NP47827 Multiple Sclerosis Medicines

The Authority seeks to establish a Framework Agreement covering Multiple Sclerosis medicines. The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape): Glatiramer acetate Interferon beta-1a Teriflunomide Dimethyl fumarate Fingolimod Natalizumab Cladribine Lots: Glatiramer acetate, Interferon beta-1a and Natalizumab; Cladribine tablets; Fingolimod, Teriflunomide and Dimethyl Fumarate

Category: goods

• Procurement method: See the tender documents
• Briefing session: Not captured. Check the original notice before relying on this.
• Eligibility and evaluation: set out in the tender documents. Check mandatory returnables, registrations and scoring before you commit.

The tender pack is published with the original notice. Use “Download Tender Pack” to open it.

Published

26 Oct 2026

First seen by Atlas

27 Oct 2026

Briefing session

Not captured. Check the original notice before relying on this.

Submission deadline

Not stated

Estimated value

£30m

Contract type

See the tender documents

Category

goods

Source

UK Find a Tender

• Manage the Bid: A structured response, from the opportunity decision to the final submission.
• Develop the Response: Clear writing, considered production and approved material ready for reuse.
• Build Bid Capability: Practical support that strengthens how your business prepares and responds.